Stockchase Opinions

Brad Willock Laboratory Corp. of American Holdings LH-N TOP PICK Dec 11, 2006

Clinical testing lab. About 40% of US tests by doctors go to either this or Quest Diagnostics (DGX-N). With an aging population, there is more testing giving more revenue. Very predictable, high cash flow driven model.
$72.380

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK
Clinical labs. 2 big players own most of the market. Expects volume will increase because of aging population needing more and more tests. Very profitable.
TOP PICK

Clinical research and testing for drug companies. They have really good visibility of growth ahead of it. (Analysts’ target: $155.00).

DON'T BUY
They did very well during Covid, but that's it.